{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:43Z","timestamp":1793898283453,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidosis type I (MPS I), is an autosomal recessive disorder caused by a deficiency in the enzyme \u03b1-L-iduronidase (IDUA), leading to the accumulation of glycosaminoglycans (GAGs) in tissues. Early diagnosis and treatment [i.e., bone marrow transplantation and\/or enzyme replacement therapy (ERT) with laronidase] are essential to prevent irreversible damage. The long-term effectiveness of exclusive ERT has been primarily described in attenuated phenotypes, while only a few cases have been reported in severe phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a retrospective analysis summarising the collective experience of disease progression in 48 patients with severe and attenuated MPS I who were treated exclusively with laronidase over a median of 10\u00a0years at the Lyon Reference Centre for Hereditary Metabolic Diseases in France. Patients were categorised by genotype and further stratified by age at treatment initiation. The study assessed the evolution of urinary excretion of GAGs, pulmonary function, cardiac involvement and evolution, height, cognitive impairment, functional status, orthopaedic and ear-nose-throat (ENT) procedures, sleep apnoea, and carpal tunnel syndrome. Descriptive statistical analysis methods were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ERT reduced the GAGus levels by 88% in severe MPS I and by 71% in attenuated MPS I, of which 47% and 65% patients, respectively achieved normal age-related GAG levels at the last follow-up. ERT provided stable or consistent improvement in forced vital capacity, slowed progression of adverse cardiac course and improved auditory transmission in majority of the severe and attenuated patients. At the last follow-up, 84% attenuated patients had normal cognitive development. In alive Hurler patients, cognitive development was very heterogenous; however, 73% patients had a developmental quotient (DQ)\u2009\u2265\u200970. Laronidase was effective in improving statural growth of attenuated patients treated before 9\u00a0years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early ERT and regular multidisciplinary management are effective in slowing disease progression in severe and attenuated patients with MPS I and helping to maintain autonomy in patients with attenuated MPS I, ensuring a better quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04157-6","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T10:55:47Z","timestamp":1765018547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of exclusive enzyme therapy (laronidase) in a cohort of patients with mucopolysaccharidosis type I"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-2366","authenticated-orcid":false,"given":"Nathalie","family":"Guffon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Pettazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pangaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Le Peillet Feuillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Journeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fouilhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"4157_CR1","unstructured":"Clarke LA. Mucopolysaccharidosis type I. 2002 Oct 31 [updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle, WA; 1993\u20132024. PMID: 20301341."},{"key":"4157_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jpeds.2016.08.033","volume":"178","author":"S Laraway","year":"2016","unstructured":"Laraway S, Mercer J, Jameson E, Ashworth J, Hensman P, Jones SA. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J Pediatr. 2016;178:219\u201326.e1.","journal-title":"J Pediatr"},{"key":"4157_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:131.","journal-title":"Orphanet J Rare Dis"},{"key":"4157_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajmg.a.63029","volume":"191","author":"D Pjetraj","year":"2023","unstructured":"Pjetraj D, Santoro L, Sgattoni C, Padella L, Zampini L, Monachesi C, et al. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I. Am J Med Genet. 2023;191:564\u201369.","journal-title":"Am J Med Genet"},{"key":"4157_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00431-011-1644-x","volume":"171","author":"K D\u2019Aco","year":"2012","unstructured":"D\u2019Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. 2012;171:911\u201319.","journal-title":"Eur J Pediatr"},{"key":"4157_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cge.13583","volume":"96","author":"LA Clarke","year":"2019","unstructured":"Clarke LA, Giugliani R, Guffon N, Jones SA, Keenan HA, Munoz-Rojas MV, et al. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): insights from the International MPS I Registry. Clin Genet. 2019;96:281\u201389.","journal-title":"Clin Genet"},{"key":"4157_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014;16:759\u201365.","journal-title":"Genet Med"},{"key":"4157_CR8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/cells9081838","volume":"9","author":"CS Hampe","year":"2020","unstructured":"Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, Wesley J, et al. Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells. 2020;9:1838.","journal-title":"Cells"},{"key":"4157_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0583-7","volume":"12","author":"BT Kiely","year":"2017","unstructured":"Kiely BT, Kohler JL, Coletti HY, Poe MD, Escolar ML. Early disease progression of Hurler syndrome. Orphanet J Rare Dis. 2017;12:1\u201310.","journal-title":"Orphanet J Rare Dis"},{"key":"4157_CR10","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"JB Eisengart","year":"2018","unstructured":"Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med. 2018;20:1423\u201329.","journal-title":"Genet Med"},{"key":"4157_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ymgme.2020.06.004","volume":"130","author":"SA Jones","year":"2020","unstructured":"Jones SA, Marsden D, Koutsoukos T, Sniadecki J, Tylee K, Phillippo S, et al. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses. Mol Genet Metab. 2020;130:255\u201361.","journal-title":"Mol Genet Metab"},{"key":"4157_CR12","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (Laronidase). Pediatrics. 2007;120:e37\u201346.","journal-title":"Pediatrics"},{"key":"4157_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229\u201340.","journal-title":"Pediatrics"},{"key":"4157_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182\u201388.","journal-title":"N Engl J Med"},{"key":"4157_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human \u03b1-L-iduronidase (laronidase). J Pediatr. 2004;144:581\u201388.","journal-title":"J Pediatr"},{"key":"4157_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13023-020-01644-w","volume":"16","author":"N Guffon","year":"2021","unstructured":"Guffon N, Pettazzoni M, Pangaud N, Garin C, Lina-Granade G, Plault C, et al. Long-term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT). Orphanet J Rare Dis. 2021;16:60.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"4157_CR17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1002\/ajmg.a.61378","volume":"179","author":"D Viskochil","year":"2019","unstructured":"Viskochil D, Clarke LA, Bay L, Keenan H, Muenzer J, Guffon N.Growth patterns for untreated individuals with MPS I: report from the international MPS I registry. Am J Med Genet. 2019;179(12):2425\u201332.","journal-title":"Am J Med Genet"},{"key":"4157_CR18","volume-title":"The Online Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2019","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Education; 2019."},{"key":"4157_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10545-010-9262-8","volume":"34","author":"CJ Gardner","year":"2011","unstructured":"Gardner CJ, Robinson N, Meadows T, Wynn R, Will A, Mercer J, et al. Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). J Inherit Metab Dis. 2011;34:489\u201397.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"4157_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13052-019-0691-1","volume":"45","author":"A Cattoni","year":"2019","unstructured":"Cattoni A, Motta S, Masera N, Gasperini S, Rovelli A, Parini R.The use of recombinant human growth hormone in patients with Mucopolysaccharidoses and growth hormone deficiency: a case series. Ital J Pediatr. 2019;45(1):93.","journal-title":"Ital J Pediatr"},{"issue":"9","key":"4157_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/gim.2016.223","volume":"19","author":"SD Grosse","year":"2017","unstructured":"Grosse SD, Lam WKK, Wiggins LD, Kemper AR.Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1. Genet Med. 2017;19(9):975\u201382.","journal-title":"Genet Med"},{"key":"4157_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","volume":"162","author":"JB Eisengart","year":"2013","unstructured":"Eisengart JB, Rudser KD, Tolar J, Orchard PJ, Kivisto T, Ziegler RS, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr. 2013;162:375\u201380.e1.","journal-title":"J Pediatr"},{"issue":"6","key":"4157_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/ana.26786","volume":"94","author":"TC Lund","year":"2023","unstructured":"Lund TC, Braunlin E, Polgreen LE, Gupta AO, Orchard PJ, Eisengart JB.Hurler syndrome glycosaminoglycans decrease in cerebrospinal fluid without brain-targeted therapy. Ann Neurol. 2023;94(6):1182\u201386.","journal-title":"Ann Neurol"},{"key":"4157_CR24","doi-asserted-by":"crossref","unstructured":"Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, et al. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab. 2015;116(1\u20132).","DOI":"10.1016\/j.ymgme.2015.06.002"},{"key":"4157_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41409-022-01886-1","volume":"58","author":"A Gardin","year":"2023","unstructured":"Gardin A, Castelle M, Pichard S, Cano A, Chabrol B, Piarroux J, et al. Long-term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients. Bone Marrow Transplant. 2023;58:295\u2013302.","journal-title":"Bone Marrow Transplant"},{"key":"4157_CR26","doi-asserted-by":"crossref","unstructured":"Komosinska-Vassev K, Blat D, Olczyk P, et al. Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population. Clin Biochem. 2014;47(13-14).","DOI":"10.1016\/j.clinbiochem.2014.06.012"},{"key":"4157_CR27","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/ajmg.a.62910","volume":"188","author":"LE Polgreen","year":"2022","unstructured":"Polgreen LE, Bay L, Clarke LA, Guffon N, Jones SA, Muenzer J, et al. Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: data from the MPS I registry. Am J Med Genet A. 2022;188:2941\u201351.","journal-title":"Am J Med Genet A"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04157-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:04:31Z","timestamp":1768341871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04157-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4157"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04157-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics committee approval was required for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All families have been informed and agreed for this publication of history and data. No images and videos of patient have been included into this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pierre Journeau is a consultant for Sanofi, Biomarin and Orthofix. Magali Pettazzoni has participation in board for Sanofi and Takeda, and has invitation to IEM Congress for Sanofi, Orchard, Biomarin. Eliane Le Peillet Feuillet is an ex-employee of Sanofi and may hold shares\/stock options in the company. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"11"}}